Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 1:46 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 457–480 of 1,666 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Metabolic Complications Clear all

Conditions: Gestational Diabetes Mellitus
Interventions: Not listed
Lead sponsor: Mike O'Callaghan Military Hospital; Federal
Eligibility: 18 Years and older · Female only
Enrollment: 643 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Nellis Air Force Base, Nevada

Conditions: Diabetes Mellitus, Type 1, Pregnancy in Diabetics, Pregnancy, High-Risk, Insulin Dependent Diabetes
Interventions: Hybrid closed loop insulin delivery system; Device
Lead sponsor: Jaeb Center for Health Research; Other
Eligibility: 18 Years and older · Female only
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 10
States / cities: Birmingham, Alabama • Aurora, Colorado • Tampa, Florida + 6 more

Conditions: Type 1 Diabetes, Diabetic Nephropathy, Diabetic Kidney Disease
Interventions: sodium bicarbonate; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 45 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Fluid Loss, Dehydration, Extreme Immaturity
Interventions: Sterile water application; Other
Lead sponsor: George Washington University; Other
Eligibility: Up to 24 Hours
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Diabetic Neuropathies, Diabetes Mellitus
Interventions: Ruboxistaurin mesylate; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2006
U.S. locations: 30
States / cities: Mesa, Arizona • Irvine, California • Long Beach, California + 27 more

Conditions: Oxalate, Primary Hyperoxaluria, Microbiome
Interventions: Not listed
Lead sponsor: VA New York Harbor Healthcare System; Federal
Eligibility: 18 Years to 80 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: New York, New York

Conditions: Diabetes During Pregnancy
Interventions: NPH, Insulin LISPRO, Insulin glulisine; Drug
Lead sponsor: Sansum Diabetes Research Institute; Other
Eligibility: 18 Years and older · Female only
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Santa Barbara, California

Conditions: Primary Hyperoxaluria Type 1, PH1
Interventions: YOLT-203, Placebo; Genetic · Drug
Lead sponsor: YolTech Therapeutics Co., Ltd; Industry
Eligibility: 6 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 4
States / cities: Birmingham, Alabama • Aurora, Colorado • St Louis, Missouri + 1 more

Conditions: Renal Insufficiency, Chronic, Hypertension, Diabetes
Interventions: Support Person, Social Norms; Other
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 73 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Healthy, Osteoporosis, Premature Ovarian Failure
Interventions: TMTDS; Drug
Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH
Eligibility: 18 Years to 32 Years · Female only
Enrollment: 250 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1999 – 2006
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Diabetic Neuropathy
Interventions: Exercise; Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 45 Years to 80 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Hines, Illinois

Conditions: Blindness, Cataract, Diabetes Mellitus, Diabetic Retinopathy, Macular Degeneration
Interventions: Not listed
Lead sponsor: National Eye Institute (NEI); NIH
Eligibility: Not listed
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1994 – 2000
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Proliferative Diabetic Retinopathy
Interventions: Propranolol; Drug
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Polycystic Ovarian Syndrome, Idiopathic Intracranial Hypertension
Interventions: Not listed
Lead sponsor: National Aeronautics and Space Administration (NASA); Federal
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2028
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Prostate Cancer, Renal Cancer, Urethral Cancer, Advanced Solid Tumor, Metastatic Castration-resistant Prostate Cancer, Solid Tumor, Adult
Interventions: Copper-64 labeled Granzyme B (64Cu-GRIP B), Positron Emission Tomography (PET); Drug · Procedure
Lead sponsor: Rahul Aggarwal; Other
Eligibility: 18 Years and older
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Diabetic Foot Ulcers
Interventions: Regranex®, Hydrogel; Drug
Lead sponsor: Southern California Institute for Research and Education; Other
Eligibility: 21 Years to 85 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 2
States / cities: Long Beach, California • Los Angeles, California

Conditions: Diabetes, Diabetic Foot Ulcer, Edema
Interventions: Conventional Therapy, Venous Stent(s); Device
Lead sponsor: Windsor Ting; Other
Eligibility: 30 Years to 64 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 1
States / cities: New York, New York

Conditions: Gestational Diabetes, Hyperglycemia
Interventions: Continuous glucose monitor, Oral Glucose Tolerance Test, Hemoglobin A1c; Device · Diagnostic Test
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Diabetes, Diabetic Macular Edema, Diabetic Retinopathy
Interventions: OCT imaging; Device
Lead sponsor: Joslin Diabetes Center; Other
Eligibility: 18 Years and older
Enrollment: 385 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 4
States / cities: Boston, Massachusetts • Wellfleet, Massachusetts • Syracuse, New York + 1 more

Conditions: Obesity, Insulin Resistance
Interventions: Spironolactone, Placebo; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 70 Years
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Gestational Diabetes
Interventions: Glyburide, Insulin; Drug
Lead sponsor: Tripler Army Medical Center; Federal
Eligibility: 18 Years and older · Female only
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2010
U.S. locations: 1
States / cities: Honolulu, Hawaii

Conditions: CKD, Diabetic Kidney Disease, Type 2 Diabetes Mellitus in Obese, Obesity, Severe Obesity
Interventions: Semaglutide 2 mg/1.5 ml (1.34 mg/ml), prefilled pen-injector for subcutaneous injection solution, Placebo 1.5 ml, prefilled pen-injector for subcutaneous injection solution; Drug
Lead sponsor: Geisinger Clinic; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 2
States / cities: Danville, Pennsylvania • Wilkes-Barre, Pennsylvania

Conditions: Gestational Diabetes, Obesity
Interventions: Lifestyle Counseling; Behavioral
Lead sponsor: Kaiser Permanente; Other
Eligibility: 18 Years and older · Female only
Enrollment: 2,480 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Oakland, California

Conditions: Obstetric Labour, Premature
Interventions: GSK221149A, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 93 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 32
States / cities: Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 26 more

Search by objective public record fields.

Utility Of Hemoglobin A1C For The Diagnosis Of Gestational Diabetes

T1D Pregnancy & Me

Effect of Urinary Alkalinization on Urine Uric Acid Precipitation and Crystallization in Adults With Type 1 Diabetes

The Application of Sterile Water to the Skin of Extremely Low Birth Weight (ELBW) Infants

Treatment of Peripheral Neuropathy in Patients With Diabetes

Descriptive Analysis of Gut Microbiome Alterations in Hyperoxaluric Patients

Comparator Trial Using Insulin Glulisine vs. Insulin Lispro for Treatment of Gestational Diabetes

Study of YOLT-203 in Children and Adults With Primary Hyperoxaluria Type 1 (PH1)

Supporting Self-Management of Healthy Behaviors in Diabetes, Kidney Disease, and Hypertension

Hormone Replacement in Young Women With Premature Ovarian Failure

Exercise-facilitated Neurorehabilitation in Diabetic Neuropathy

Long Term Follow-Up of Diabetic Retinopathy

Propranolol for Diabetic Retinopathy

Astronaut Vision Issues in a Ground Analog Population: Polycystic Ovary Syndrome

64Cu-GRIP B in Patients With Advanced Malignancies

Evaluation of Windowed Casts With and Without Regranex® Gel for Healing Diabetic Neuropathic Ulcers

The Mount Sinai Diabetic Foot Ulcer Prospective Trial

Early Investigation of Glucose Monitoring After Gestational Diabetes Pilot

OCT Screening for Diabetic Macular Edema at Primary Diabetes Care Visits

Mineralocorticoid Receptor and Obesity Induced Cardiovascular Complications

Glyburide Compared to Insulin in the Management of White's Classification A2 Gestational Diabetes

Effect of Subcutaneous Semaglutide on Kidney Transplant Candidacy

Diabetes Prevention Strategies in Women With Gestational Diabetes Mellitus (GDM)

The Safety, Tolerability And Metabolism Of GSK221149A, In Pregnant Women (30-36 Weeks), In Pre-Term Labor